{
    "clinical_study": {
        "@rank": "82319", 
        "acronym": "REVIVED-BCIS2", 
        "arm_group": [
            {
                "arm_group_label": "Percutaneous Coronary Intervention and Optimal Medical Therapy", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Optimal Medical Therapy alone", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess whether percutaneous coronary intervention (angioplasty of the heart\n      arteries) can improve survival and reduce hospitalization in patients with heart failure due\n      to coronary disease, who have been treated with the best contemporary medical therapy."
        }, 
        "brief_title": "Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Ischemia", 
                "Ventricular Dysfunction", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        ALL of the following:\n\n          1. Poor left ventricular function (EF\u226430%)\n\n          2. Extensive coronary disease (BCIS-1 Jeopardy Score \u22656)\n\n          3. Viable myocardium in \u226530% of dysfunctional segments\n\n        Main Exclusion Criteria:\n\n          1. Significant angina (\u2265Canadian Cardiovascular Society class 3)\n\n          2. Myocardial infarction < 6 weeks previously\n\n        Other Exclusions\n\n          1. Decompensated heart failure requiring inotropic support, invasive or non-invasive\n             ventilation or Intra-aortic Balloon Pump/left ventricular assist device therapy <72\n             hours prior to randomization\n\n          2. Sustained Ventricular Tachycardia/Ventricular Fibrillation or appropriate Implantable\n             Carioverter Defbrillator discharges <72 hours prior to randomization\n\n          3. More than mild aortic stenosis or mild aortic regurgitation on echocardiography\n\n          4. Contra-indications to percutaenous cornoary intervention, including\n             contra-indications to Aspirin or Clopidogrel or Heparin\n\n          5. Age <18 yrs\n\n          6. Bleeding diathesis or Warfarin therapy with INR (International Normalized Ration)>3.5\n\n          7. Active internal bleeding (except menstruation)\n\n          8. Platelet count < 100,000 cells/mm3) at randomization\n\n          9. Hemoglobin < 90 g/L at randomization\n\n         10. Estimated Glomerular Filtration Rate < 25 ml/min, unless established on dialysis\n\n         11. Women who are pregnant\n\n         12. Previously enrolled in REVIVED-BCIS2 or current enrollment in other study that may\n             affect REVIVED-BCIS2 outcome data\n\n         13. Life expectancy < 1 yr due to non-cardiac pathology"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "700", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01920048", 
            "org_study_id": "ISRCTN45979711", 
            "secondary_id": "ISRCTN45979711"
        }, 
        "intervention": [
            {
                "arm_group_label": "Percutaneous Coronary Intervention and Optimal Medical Therapy", 
                "intervention_name": "Percutaneous Coronary Intervention", 
                "intervention_type": "Procedure", 
                "other_name": "Coronary angioplasty/stents"
            }, 
            {
                "arm_group_label": [
                    "Percutaneous Coronary Intervention and Optimal Medical Therapy", 
                    "Optimal Medical Therapy alone"
                ], 
                "description": "The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines", 
                "intervention_name": "Drug Therapy for Heart Failure", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Percutaneous Coronary Intervention and Optimal Medical Therapy", 
                "description": "The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.", 
                "intervention_name": "Device Therapy for Heart Failure", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart Failure", 
            "Ventricular Dysfunction", 
            "Ischemic Cardiomyopathy", 
            "Ischemic Heart Disease", 
            "Revascularization", 
            "Percutaneous Coronary Intervention", 
            "Randomized Control Trial", 
            "Implantable Cardioverter Defibrillator"
        ], 
        "lastchanged_date": "August 8, 2013", 
        "location": {
            "contact": {
                "email": "Lucy.Clack@gstt.nhs.uk", 
                "last_name": "Lucy Clack", 
                "phone": "+44 20 7188 6271"
            }, 
            "contact_backup": {
                "email": "Sophie.Jones@gstt.nhs.uk", 
                "last_name": "Sophie Jones", 
                "phone": "+44 20 7188 7188"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SE1 7EH"
                }, 
                "name": "Guy's and St Thomas' Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED): a Randomized Comparison of Percutaneous Coronary Intervention (With Optimal Medical Therapy) Versus Optimal Medical Therapy Alone for Treatment of Heart Failure Secondary to Coronary Disease", 
        "other_outcome": {
            "description": "Health Economic Analysis", 
            "measure": "Health Service Resource Use", 
            "safety_issue": "No", 
            "time_frame": "1 to 66 months (min follow-up duration: 24 months)"
        }, 
        "overall_contact": {
            "email": "Richard.Evans@lshtm.ac.uk", 
            "last_name": "Richard Evans", 
            "phone": "+44 20 7927 2665"
        }, 
        "overall_contact_backup": {
            "email": "Rosemary.Knight@lshtm.ac.uk", 
            "last_name": "Rosemary Knight", 
            "phone": "+44 20 7927 2473"
        }, 
        "overall_official": {
            "affiliation": "King's College London", 
            "last_name": "Divaka Perera, MB BChir, MA, MD, FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: National Institute for Health Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "All-cause death or Hospitalization for Heart Failure", 
            "safety_issue": "No", 
            "time_frame": "1 to 66 months (min follow-up duration: 24 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01920048"
        }, 
        "responsible_party": {
            "investigator_affiliation": "King's College London", 
            "investigator_full_name": "Divaka Perera", 
            "investigator_title": "Consultant Cardiologist and Reader in Interventional Cardiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Quality of Life Scores and Functional Status", 
                "safety_issue": "No", 
                "time_frame": "6 months, 1 year, 2 years"
            }, 
            {
                "measure": "Left Ventricular Ejection Fraction", 
                "safety_issue": "No", 
                "time_frame": "6 months, 1 year"
            }, 
            {
                "measure": "Cardiovascular death, myocardial infarction, cerebrovascular accident, major bleeding or unplanned revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Cardiovascular Death", 
                "safety_issue": "No", 
                "time_frame": "1 to 66 months (min follow-up duration: 24 months)"
            }, 
            {
                "measure": "Appropriate Implantable Cardioverter Defibrillator Therapy", 
                "safety_issue": "No", 
                "time_frame": "6 months, 1 year, 2 years"
            }, 
            {
                "measure": "Acute Myocardial Infarction", 
                "safety_issue": "No", 
                "time_frame": "1 to 66 months (min follow-up duration: 24 months)"
            }, 
            {
                "measure": "Unplanned further revascularization", 
                "safety_issue": "No", 
                "time_frame": "1 to 66 months (min follow-up duration: 24 months)"
            }, 
            {
                "measure": "Brain-type Natriuretic Peptide level", 
                "safety_issue": "No", 
                "time_frame": "6 months, 1 year, 2 years"
            }, 
            {
                "measure": "Major Bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "6 months, 1 year, 2 years"
            }
        ], 
        "source": "King's College London", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute for Health Research (Health Technology Assessment Programme)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "London School of Hygiene and Tropical Medicine (Clinical Trials Unit)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of York (Centre for Health Economics)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guy's and St Thomas' Hospital NHS Foundation Trust", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "King's College London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}